---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019633"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:33:38.521217+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma reports Q1 2023 cash of $117.6M; Phase 3 sarcoidosis trial enrolling

## Summary
- Cash, equivalents and investments of $117.6M as of March 31, 2023; $48.1M net from February stock offering.
- Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolling in U.S., Europe and Japan; up to 264 subjects.
- Phase 2 proof-of-concept study in SSc-ILD expected to initiate Q3 2023; 25 patients, multiple U.S. centers.
- R&D expenses $9.4M and G&A expenses $3.4M for Q1 2023; cash runway projected into 2026.
- Multiple efzofitimod presentations planned at ATS 2023 International Conference May 19-24.

## SEC filing metadata
- accession: 0000950170-23-019633
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017023019633/0000950170-23-019633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017023019633/life-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019633
- JSON: https://secwatch.observer/filing/0000950170-23-019633.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019633.txt

## Key facts
- Earnings Releases
  aTYR PHARMA INC updated its three months ended March 31, 2023 guidance (reaffirmed).
  - Period: three months ended March 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On May 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017023019633/0000950170-23-019633-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.